复方丹参滴丸改善非增生型糖尿病视网膜病变患者神经节细胞层及神经纤维层厚度的临床研究  

A study on the improvement of ganglion cell layer and nerve fibre layer thickness in non-proliferative diabetic retinopathy by Compound Danshen Drip Pill

作　　者：张瑛 周慧 陆小凡 徐冲 沈磊 曹维 孙宇 ZHANG Ying;ZHOU Hui;LU Xiaofan;XU Chong;SHEN Lei;CAO Wei;SUN Yu(Department of Endocrinology and Metabolism,The Affiliated Suqian Hospital of Xuzhou Medical University,Suqian 223800,China;Department of Ophthalmology,The Affiliated Suqian Hospital of Xuzhou Medical University,Suqian 223800,China)

机构地区：[1]徐州医科大学附属宿迁医院内分泌科,宿迁223800 [2]徐州医科大学附属宿迁医院眼科,宿迁223800

出　　处：《天津中医药》2025年第5期573-577,共5页Tianjin Journal of Traditional Chinese Medicine

基　　金：江苏省中医药科技发展计划(MS2021094);宿迁市重点研发计划项目(S202202)。

摘　　要：[目的]探究复方丹参滴丸改善非增生型糖尿病视网膜病变(NPDR)患者神经节细胞层(GCL)及神经纤维层厚度(RNFL)的临床疗效。[方法]选取2022年1月—2023年6月于徐州医科大学附属宿迁医院内分泌科门诊或住院的NPDR患者共计70例,收集患者基线临床资料,随机化分为治疗组与对照组各35例。治疗组为在对照组基础上加用复方丹参滴丸治疗,具体方法为试验开始后服用复方丹参滴丸,每次20丸,每日3次,疗程24周;对照组为常规治疗组,具体方法为在门诊或住院部在专科医师指导下根据指南对DR的可控危险因素如血糖、血压、血脂等进行综合管理。受试者在试验开始前和结束后完成两次访视,通过光学相干断层扫描(OCT)分别检测黄斑区视神经节层(GCL)厚度和视盘周围神经纤维层(RNFL)治疗前后的厚度。[结果]两组患者的基线资料比较差异无统计学意义(P>0.05)。服用复方丹参滴丸24周后,与治疗前相比,治疗组黄斑区GCL和视盘周围RNFL不同区域的厚度均得到显著改善(P<0.05);与对照组相比,治疗组黄斑区GCL和视盘周围RNFL不同区域的厚度均显著增加(P<0.05)。[结论]复方丹参滴丸可以增加NPDR患者视网膜神经层厚度,改善早期DR神经细胞损害,视网膜神经元细胞可能是复方丹参滴丸治疗DR的重要靶点。[Objective]To investigate the clinical efficacy of Compound Danshen Drip Pills in improving the ganglion cell layer(GCL)and retinal nerve fibre layer(RNFL)in patients with non-proliferative diabetic retinopathy(NPDR).[Methods]A total of 70 NPDR patients who were outpatients or inpatients in the department of endocrinology,The Affiliated Suqian Hospital of Xuzhou Medical University were selected from January 2022 to June 2023,and the baseline clinical data of the patients were collected,and they were randomly divided into 35 cases each in the treatment group and the control group.The treatment group was based on the control group with the addition of the Compound Danshen Drip Pills,which consisted of taking Compound Danshen Drip Pills,20 pills each time,three times a day for a period of 24 weeks after the start of the study;the control group was the conventional treatment group,which consisted of comprehensive management of the controllable risk factors of DR,such as glucose,blood pressure and lipids,according to the guidelines of the specialists in outpatient clinics or inpatient departments.Subjects attended two visits before and after the study,and the thickness of the optic nerve ganglion layer(GCL)in the macula and the thickness of the peripheral nerve fibre layer(RNFL)in the optic nerve head were measured by optical coherence tomography(OCT)before and after treatment.[Results]There was no statistically significant difference between the baseline data of the two groups(P>0.05).After taking Compound Danshen Dropping Pills for 24 weeks,the thickness of the macular GCL and various areas of the RNFL around the optic disc in the treatment group were significantly improved compared with the pre-treatment period(P<0.05);the thickness of the macular GCL and various areas of the RNFL around the optic disc in the treatment group were significantly increased compared with the control group(P<0.05).[Conclusions]Compound Danshen Drip Pill can increase retinal nerve layer thickness and improves early DR nerve cell damage i

关 键 词：非增生型糖尿病视网膜病变 复方丹参滴丸 神经节细胞层 神经纤维层 

分 类 号：R587.2[医药卫生—内分泌]